Influenza Vaccination Strategy for Patients With Hematologic Malignancy

Summary

This randomized controlled trial evaluates and compares the immunogenicity of three different influenza vaccine formulations: high-dose trivalent (HD-IIV3), MF59-adjuvanted quadrivalent (aIIV4), and standard-dose trivalent (SD-IIV3) vaccines. The study population consists of patients with hematologic malignancies, including those undergoing autologous stem cell transplantation or CAR-T cell therapy. The primary goal is to identify which vaccine strategy elicits the most robust antibody and T cell-mediated immune responses in this severely immunocompromised population

Eligibility

Inclusion Criteria:

* Adults aged 19 years or older
* Confirmed diagnosis of hematologic malignancy, including:

non-Hodgkin lymphoma, Hodgkin lymphoma, acute leukemia, chronic leukemia, or plasma cell disorders

Exclusion Criteria:

* Difficulty with repeated venipuncture or blood sampling (e.g., poor vascular access or bleeding tendency)
* Cognitive or psychiatric impairment precluding understanding of or cooperation with study procedures
* Known hypersensitivity to influenza vaccine components
* Influenza vaccination within the preceding 6 months
* Any other condition deemed clinically inappropriate for study participation at investigator discretion

Conditions4

Interventions1

Browse More Trials